OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
EPIC.CD56

1CM Inc

PharmaceuticalsVerified

1CM Inc maintains a conservative capital structure with a debt-to-equity ratio of 0.12, indicating limited leverage. The company's liquidity position is characterized by a current ratio of 3.17, suggesting strong short-term liquidity. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity (ROE) of 1.68% and a return on assets (ROA) of 1.16%, both below the typical thresholds for high-performing firms in the pharmaceuticals industry. These returns suggest that the company is generating modest returns relative to its equity and asset base, which may indicate inefficiencies or a challenging market environment. The company's revenue is derived from multiple segments, including cannabis, liquor, tobacco, and nicotine. However, the financial snapshot does not provide a breakdown of revenue by segment or geography, making it difficult to assess concentration risk. The lack of detailed segment data limits the ability to evaluate exposure to specific markets or products. The company's growth trajectory is not clearly defined in the provided data. The financial snapshot does not include historical revenue data or forward-looking guidance, which would be necessary to assess growth trends. The absence of such data makes it challenging to determine whether the company is expanding or contracting in its core markets. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's capital structure is relatively stable, with a low level of long-term debt and a manageable equity base. However, the negative net cash position after debt is a concern that could affect the company's ability to fund operations or invest in growth opportunities. Recent events and filings are not detailed in the provided data, so there is no information on recent strategic moves, regulatory changes, or other developments that could impact the company's performance. The lack of recent event data limits the ability to assess the company's current strategic direction and external challenges.

30-day price · EPIC.CD-0.02 (-9.1%)
Low$0.14High$0.17Close$0.15As of17 May, 00:00 UTC
Profile
Company1CM Inc
TickerEPIC.CD
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. 1CM Inc is a Canada-based cannabis company that provides B2B and B2C solutions through its One Cannabis Market technology platform, and offers cannabis and liquor products under its Cost Cannabis and Costcan Liquor brands.

Classification. 1CM Inc is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector and the Pharmaceuticals industry, with a confidence level of 0.92.

1CM Inc maintains a conservative capital structure with a debt-to-equity ratio of 0.12, indicating limited leverage. The company's liquidity position is characterized by a current ratio of 3.17, suggesting strong short-term liquidity. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity (ROE) of 1.68% and a return on assets (ROA) of 1.16%, both below the typical thresholds for high-performing firms in the pharmaceuticals industry. These returns suggest that the company is generating modest returns relative to its equity and asset base, which may indicate inefficiencies or a challenging market environment. The company's revenue is derived from multiple segments, including cannabis, liquor, tobacco, and nicotine. However, the financial snapshot does not provide a breakdown of revenue by segment or geography, making it difficult to assess concentration risk. The lack of detailed segment data limits the ability to evaluate exposure to specific markets or products. The company's growth trajectory is not clearly defined in the provided data. The financial snapshot does not include historical revenue data or forward-looking guidance, which would be necessary to assess growth trends. The absence of such data makes it challenging to determine whether the company is expanding or contracting in its core markets. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's capital structure is relatively stable, with a low level of long-term debt and a manageable equity base. However, the negative net cash position after debt is a concern that could affect the company's ability to fund operations or invest in growth opportunities. Recent events and filings are not detailed in the provided data, so there is no information on recent strategic moves, regulatory changes, or other developments that could impact the company's performance. The lack of recent event data limits the ability to assess the company's current strategic direction and external challenges.
Key takeaways
  • 1CM Inc maintains a conservative capital structure with a low debt-to-equity ratio of 0.12.
  • The company's ROE of 1.68% and ROA of 1.16% indicate modest returns relative to industry benchmarks.
  • The current ratio of 3.17 suggests strong short-term liquidity, but the negative net cash position after debt is a concern.
  • The company's revenue is derived from multiple segments, but the lack of detailed segment data limits the ability to assess concentration risk.
  • The risk assessment indicates a medium liquidity risk and a low dilution risk, with a stable capital structure.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCAD
Revenue$73.4M
Gross profit$15.5M
Operating income$713.9k
Net income$484.9k
R&D
SG&A
D&A
SBC
Operating cash flow$2.7M
CapEx-$250.6k
Free cash flow$1.5M
Total assets$41.9M
Total liabilities$13.0M
Total equity$28.9M
Cash & equivalents
Long-term debt$3.4M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$28.9M
Net cash-$3.4M
Current ratio3.2
Debt/Equity0.1
ROA1.2%
ROE1.7%
Cash conversion5.6%
CapEx/Revenue-0.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricEPIC.CDActivity
Op margin1.0%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin0.7%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin21.1%19.7% medp25 19.7% · p75 39.8%above median
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-0.3%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity12.0%71.3% medp25 19.0% · p75 91.7%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 23:31 UTC#bd063ca8
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 23:32 UTCJob: 2851278d